Abcellera Biologics Inc. , of Vancouver, British Columbia, published preclinical data on bamlanivimab (LY-CoV555), a monoclonal antibody targeting SARS-CoV-2, in Science Translational Medicine . X-ray crystallography and electron microscopy showed bamlanivimab binds to the spike protein in an area that overlaps the ACE2 binding site in both the up and down positions. In nonhuman primates, doses of 2.5 mg/kg and higher serum concentrations produced maximum reduction of viral replication as ...